Diglycolstearinsaeureamid | 32425-87-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Diglycolstearinsaeureamid
• 英文别名: 2-(2-Hydroxyethoxy)ethyl stearamide；N-[2-(2-hydroxyethoxy)ethyl]octadecanamide
• CAS: 32425-87-9
• 化学式: C₂₂H₄₅NO₃
• 分子量: 371.604
• InChiKey: LFKAKTJJVHTSDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  26
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS
  申请人：GRI Bio, Inc.

  公开号：EP3229811B1

  公开（公告）日：2021-02-24
• REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS, E.G., SUBCUTANEOUSLY ADMINISTERED THERAPEUTIC PROTEINS
  申请人：ModernaTX, Inc.

  公开号：US20200109420A1

  公开（公告）日：2020-04-09

  This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering nucleic acids in vivo. These compositions have reduced immune activation resulting in accelerated blood clearance and/or anti-drug antibodies and they have an improved toxicity profile and therapeutic index in vivo.
• [EN] PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS<br/>[FR] PRÉVENTION ET TRAITEMENT DE PATHOLOGIES INFLAMMATOIRES
  申请人：GLYCOREGIMMUNE INC

  公开号：WO2016094226A1

  公开（公告）日：2016-06-16

  In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.